MTD vs. TEM: Mettler-Toledo vs. Tempus AI Stock Comparison
How do Mettler-Toledo (MTD) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Mettler-Toledo (MTD) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
Mettler-Toledo (MTD) carries decades of public-market history since November 14, 1997, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the MTD side.
| Profile Item | MTD | TEM |
|---|---|---|
| Name | Mettler-Toledo International Inc. | Tempus AI Inc Class A Common Stock |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 34.25 billion USD | 13.87 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 14, 1997 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MTD | TEM |
|---|---|---|
| Total Return (1Y) | 21.58% | 16.25% |
| Total Return (3Y, Annualized) | 19.54% | -- |
| Total Return (5Y, Annualized) | 2.36% | -- |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Mettler-Toledo (MTD) is closer to market-like at 1.15 — a noticeable difference in market-sensitivity profile.
| Metric | MTD | TEM |
|---|---|---|
| Volatility (1Y, Annualized) | 31.70% | 76.08% |
| Beta (5Y) | 1.15 | 3.34 |
| Max Drawdown (5Y) | -43.47% | -59.76% |
| Avg. Volume (3M) | 197.80K | 7.20M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MTD | TEM |
|---|---|---|
| Sharpe Ratio (1Y) | 0.55 | 0.16 |
| Sortino Ratio (1Y) | 0.75 | 0.26 |
Profitability
ROE (TTM)
Mettler-Toledo (MTD) has no ROE value reported for this period; Tempus AI (TEM) reports a negative figure of -37.55%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-37.55%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- TEM
- -37.55%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Mettler-Toledo (MTD) reports 22.25%, ranking against industry peers normally.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.54%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- TEM
- -12.54%
- Min
- -17.05%
Operating Margin (TTM)
Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Mettler-Toledo (MTD) reports 28.70%, ranking against industry peers normally.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-13.82%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- TEM
- -13.82%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MTD | TEM |
|---|---|---|
| ROE (TTM) | -- | -37.55% |
| ROA (TTM) | 20.09% | -7.36% |
| Net Margin (TTM) | 22.25% | -12.54% |
| Operating Margin (TTM) | 28.70% | -13.82% |
| Gross Margin (TTM) | 59.16% | 64.46% |
Growth
Revenue Growth
Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Mettler-Toledo (MTD) at 3.98% is closer to the peer norm — faster top-line expansion for TEM.
EPS Growth
Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.
Growth Metrics
| Metric | MTD | TEM |
|---|---|---|
| Revenue Growth (YoY) | 3.98% | 83.41% |
| Revenue Growth (3Y CAGR) | 0.90% | 58.29% |
| EPS Growth (YoY) | 3.88% | -- |
| EPS Growth (3Y CAGR) | 3.06% | -- |
Financial Strength
Current Ratio (MRQ)
Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- TEM
- 2.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Debt sits unusually high against shareholders’ equity for both Mettler-Toledo (MTD) at 26.06 and Tempus AI (TEM) at 2.86 — each debt-to-equity ratio is above its industry benchmark range.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- TEM
- 2.86
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MTD | TEM |
|---|---|---|
| Current Ratio (MRQ) | 1.10 | 2.61 |
| Debt / Equity (MRQ) | 26.06 | 2.86 |
| Net Debt / EBITDA | 1.58 | -- |
Dividends
Dividend Yield (TTM)
Neither Mettler-Toledo (MTD) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Mettler-Toledo (MTD) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MTD | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- TEM
- --
P/S Ratio (TTM)
On P/S ratio, both Mettler-Toledo (MTD) at 8.16 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.19
- Max
- 58.18
- Q3
- 25.77
- TEM
- 9.19
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Measured against book value, both Mettler-Toledo (MTD) at 442.71 and Tempus AI (TEM) at 27.66 look expensive — each P/B ratio sits above its industry’s benchmark range.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.66
- TEM
- 27.66
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MTD | TEM |
|---|---|---|
| P/E Ratio (TTM) | 37.38 | -- |
| P/S Ratio (TTM) | 8.16 | 9.19 |
| P/B Ratio (MRQ) | 442.71 | 27.66 |
| Free Cash Flow Yield (TTM) | 1.97% | 0.30% |